Trooperstocks
1週前
$COEP NEWS: Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies
PR Newswire
Thu, December 26, 2024 at 8:15 AM EST
In This Article:
COEP, COEPW
Coeptis Aims to Bring AI Innovation in Biotechnology and Technology
WEXFORD, Pa., Dec. 26, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company specializing in innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, proudly announces the completion of its acquisition of the NexGenAI Affiliates Network platform alongside the official launch of Coeptis Technologies. This new division is strategically aimed at diversifying the company's growth potential.
The acquisition of the NexGenAI Affiliates Network platform, which was developed by NexGenAI Solutions Group, Inc. and its affiliates ("NexGenAI"), offers what Coeptis views as groundbreaking AI-powered marketing software and advanced robotic process automation (RPA) capabilities. This transformative AI-powered tool is designed to empower marketers to process vast amounts of data, optimize campaigns, enhance customer engagement, and streamline operations—crucial elements in the highly regulated sectors of biotech, pharmaceutical, and multi-level marketing (MLM) industries.
Dave Mehalick, President and CEO of Coeptis Therapeutics, stated, "We are excited to integrate the NexGenAI Affiliates Network platform and its AI and RPA-driven tools into our offerings. In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is critical."
Anshuman Dash, Lead Advisory behind the development of the NexGenAI Affiliates Network platform, commented, "The integration of NexGenAI's innovative AI-powered marketing solutions with Coeptis Therapeutics' forward-thinking approach marks a transformative step forward. This acquisition aligns nicely with Coeptis' mission to drive innovation in highly regulated industries, revolutionize marketing strategies and operational efficiencies and ultimately deliver greater value to the partners and the industries served."
This acquisition reflects Coeptis' commitment to leveraging advanced technologies to enhance its capabilities and drive innovation within the biopharmaceutical sector. By incorporating NexGenAI's AI-powered marketing solutions, Coeptis aims to provide state-of-the-art tools to companies seeking to overcome marketing challenges in competitive and highly regulated industries.
Dave Mehalick elaborated further on the NexGenAI Affiliates Network platform acquisition, stating, "In highly competitive industries such as biotech, pharma, and MLM, having advanced tools to optimize marketing, streamline operations, and drive measurable results is not just beneficial—it's essential for our success."
About Coeptis Therapeutics Holdings, Inc.:
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institute. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com
About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned subsidiary NexGenAI Solutions Group, Inc., has developed a proprietary suite of advanced tools that power the NexGenAI Affiliates Network platform. These tools, featuring AI-driven marketing software and robotic process automation capabilities, are designed to optimize campaigns, streamline operations, and provide actionable, data-driven insights. NexGenAI's platform provides cutting-edge AI-driven solutions that revolutionize business operations across various sectors. By leveraging artificial intelligence, NexGenAI empowers companies to automate processes, optimize efficiency, and drive sustainable growth. For more information on NexGenAI, visit nexgenai.io.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-makes-bold-strides-in-innovation-with-the-acquisition-of-nexgenai-affiliates-network-platform-and-launch-of-coeptis-technologies-302339010.html
SOURCE Coeptis Therapeutics, Inc.
Trooperstocks
3週前
$COEP NEWS- FULL PRESS "Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies"
PR Newswire
Thu, December 12, 2024 at 8:00 AM EST
In This Article:
COEP
+16.47%
COEPW
0.00%
Coeptis Technologies Signs Binding Letter of Intent to Acquire Key Assets from a Risk Mitigation Software Company with 10,000 customers in over 100 countries, Expanding into the Booming Data Security Sector following the upcoming acquisition of NexGenAI Affiliates Network
WEXFORD, Pa., Dec. 12, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce the official launch of Coeptis Technologies, a new division aimed at diversifying and enhancing the company's growth potential. This strategic move underscores Coeptis' commitment to maximizing shareholder value and capitalizing on high-growth opportunities across different sectors.
(PRNewsfoto/Coeptis Therapeutics, Inc.)
(PRNewsfoto/Coeptis Therapeutics, Inc.)
In line with this initiative, Coeptis Technologies has signed a binding Letter of Intent (LOI) with a Risk Mitigation Software Company who is a leading company in the data security software industry with over 10,000 customers in over 100 countries. This LOI outlines the acquisition of significant technology assets, representing a key step in broadening our operational scope and entering the burgeoning data security market.
The acquisition will involve the transfer of their proprietary technologies, including its Data Placement Manager and Sensitive Content Manager solutions, to Coeptis' newly established technology subsidiary. This development not only positions Coeptis as a formidable player in the data security field but also signals our dedication to innovation and long-term value creation for our shareholders. The transaction is anticipated to close upon the finalization of definitive agreements. The current President and CEO of the Risk Mitigation Software Company, will join Coeptis management team to lead this new technology division, ensuring that Coeptis leadership remains focused on both our biotechnology assets and the expansion into technology without distraction. This strategic move underscores Coeptis' commitment to maximizing shareholder value and capitalizing on high-growth opportunities across different sectors.
Dave Mehalick, President and CEO of Coeptis Therapeutics, commented, "We are embarking on an exciting journey of expansion that will not only enhance our presence in the biopharmaceutical sector but also venture into the high-growth technology sector. By establishing Coeptis Technologies, we are strategically positioning ourselves to leverage the unique opportunities present in these two dynamic industries. Our commitment to deliver unprecedented value to our shareholders is stronger than ever as we pursue innovative solutions that address the evolving needs of the market."
Dave Mehalick continued, "This acquisition represents a significant milestone in Coeptis' strategic evolution. By integrating the high-value technology assets of this new acquisition, we are obtaining well-established, revenue-generating assets that will enable us to position ourselves for long-term growth in the rapidly expanding data security industry. The acquisition will keep our new technology team very busy in the coming months as they bring over 10,000 customers in over 100 countries to Coeptis Technologies and they provide a modern approach to data governance and security by identifying and protecting all sensitive data regardless of location, platform, or format. Their framework helps customers prioritize risk, identify security gaps, and implement effective data protection and privacy management strategies. The addition of these innovative data security solutions will not only diversify our portfolio but also allow us to explore new markets. We are particularly thrilled to welcome its CEO to our leadership team, as his expertise will be pivotal in maximizing the value of these assets and driving our next phase of growth, which aligns with our recently announced upcoming acquisition of NexGenAI Affiliates Network. More information on this acquisition will be announced in the coming weeks."
Dave Mehalick also commented on the NexGenAI acquisition, stating, "We are excited to integrate NexGenAI Affiliates Network and its groundbreaking AI and RPA-driven tools into our new technology division. This integration is poised to enhance the performance of both our biotechnology and technology sectors. In highly competitive industries such as biotech, pharma, and MLM, where regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is not just beneficial—it's essential for our success."
The asset acquisition of the Risk Mitigation Software Company is subject to customary closing conditions, including the execution of definitive agreements and requisite approvals by both parties. Coeptis anticipates completing this transaction in early 2025.
This strategic expansion into Coeptis Technologies comes at a pivotal time when the technology sector continues to experience rapid growth, with many of the market's top-performing stocks being technology-driven. By leveraging the innovative AI and RPA-driven tools from NexGenAI and the transformative data security technologies from the upcoming acquisition, Coeptis is not only diversifying its capabilities but is also positioning itself to thrive in one of the most dynamic and lucrative industries.
About Coeptis Therapeutics Holdings, Inc.:
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institute. The Company is headquartered in Wexford, PA. For more information on Coeptis visit [https://coeptistx.com/](https://coeptistx.com/).
About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned subsidiary NexGenAI Solutions Group, Inc., has developed a proprietary suite of advanced tools that power the NexGenAI Affiliates Network platform. These tools, featuring AI-driven marketing software and robotic process automation capabilities, are designed to optimize campaigns, streamline operations, and provide actionable, data-driven insights. NexGenAI's platform provides cutting-edge AI-driven solutions that revolutionize business operations across various sectors. By leveraging artificial intelligence, NexGenAI empowers companies to automate processes, optimize efficiency, and drive sustainable growth. For more information on NexGenAI, visit [nexgenai.io](nexgenai.io).
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
For Coeptis Therapeutics, Inc.:
IR@coeptistx.com
Cision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-unveils-new-technology-division-coeptis-technologies-302329739.html
SOURCE Coeptis Therapeutics, Inc.
Trooperstocks
2年前
NEWS: Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics
Tue, April 18, 2023 at 7:30 AM EDT
In this article: COEP
+8.39%
Recommendation Rating
Buy
Proposed transaction would provide Coeptis with two clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML) and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors
Clinical data from AML Clinical Trial Expected during 2H 2023
WEXFORD, Pa. , April 18, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced it has entered into a binding term sheet with Deverra Therapeutics, Inc. ("Deverra Therapeutics") pursuant to which it has obtained an exclusive right, until August 31, 2023, to negotiate towards the acquisition or license of assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages. Deverra Therapeutics is currently advancing clinical programs investigating these technologies in relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) and patients hospitalized with respiratory viral infections.
The transaction, if finalized, would provide Coeptis with, among other assets, exclusive rights to two FDA approved Investigational New Drug (IND) applications and two Phase 1 clinical trials (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections. In addition, Coeptis would gain access to a highly scalable allogeneic cellular immunotherapy platform that is being developed to generate and deliver off-the-shelf (no HLA matching), cost effective, on demand cell therapies to a broad patient population. Deverra expects phase I clinical trial data from its AML study to be complete during 2H 2023.
Additionally, subject to the successful negotiation and completion of any proposed transaction, Deverra Therapeutics' current Scientific Founder, Chief Scientific Officer and EVP, Research & Development, Colleen Delaney, MD, would be expected to assume the position of Chief Scientific and Medical Officer at Coeptis Therapeutics. Dr. Delaney is a world-renowned expert in cell and gene therapy research with more than 20 years' experience in the translation of scientific discovery to clinical practice, including all aspects of cell therapy product development.
"This transaction would greatly expand Coeptis' technology portfolio by incorporation of a cutting-edge allogeneic cell therapy platform with extensive safety and clinical data and align itself with leading experts in the field of cell and gene therapy," said Dave Mehalick, President and CEO of Coeptis Therapeutics. Mr. Mehalick continued, "The addition of these clinical and pre-clinical immune effector cell programs would significantly diversify our R&D capabilities and bring a clinical pipeline with multiple novel approaches to combination cellular immunotherapy approaches, not yet achieved by others. Importantly, the substantial capabilities of the allogeneic cell therapy platform would open new pathways for Coeptis to consider expanding its cell-based therapies beyond autologous CAR T. We are excited about the possibility of exploring the application of both the SNAP-CAR and GEAR technologies to allogeneic, off-the-shelf immune effector cells. The NK and macrophage (MAC) immune effector cell generation from Deverra's platform combined with Coeptis' target specific CARs has the potential to result in development of allogeneic NK and MAC cell therapies."
Dr. Delaney stated: "Deverra's allogeneic cell therapy platform has been in use clinically since 2006, and we have generated significant clinical and safety data since that time. This platform has been shown to provide extreme flexibility and optionality in the generation and modification of multiple distinct immune effector cell types from a single platform. We are excited about the prospect of bringing together our established allogeneic cell platform with the novel targets and technologies from Coeptis to generate first-in-class allogeneic cell therapies to treat a wide range of life-threatening disorders in a cost effective and clinically accessible way."
The proposed transaction is subject to confirmatory due diligence, negotiation and execution of definitive documentation based on agreed terms and other closing conditions, including third party approvals, as well as a right of first refusal in place that a third party possesses and will have a right to exercise. There can be no assurance that the parties will reach a definitive agreement related to the proposed acquisition or license of assets or that, even if any such agreement is reached, any such transaction will be successfully consummated.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.
About Deverra Therapeutics
Deverra Therapeutics is a privately held clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf (no matching required) cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. Deverra is the only company with a proprietary and clinically proven stem cell expansion technology that also serves as starting material for generation of multiple fully functional immune effector cells that can also be engineered to be potent killers of cancer cells. Deverra was a pioneer developing universal non-HLA matched allogeneic and off-the-shelf cell therapies that have been utilized in multiple clinical trials with no safety concerns.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Global Market; (2) the risk that, if the Deverra transaction closes it will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the targeted Deverra assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Jon Nugent
jnugent@tiberend.com
Media
David Schemelia
dschemelia@tiberend.com
Cision
Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-signs-agreement-to-acquire-allogeneic-immuno-oncology-nk-platform-in-phase-1-clinical-trials-from-deverra-therapeutics-301799765.html
Hot Features
プレミアム
登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
tw0122
4日前
TheFinalCD
4日前
TrendTrade2016
4日前
pumpnass
4日前
glenn1919
1週前
AKAPAK
3週前
Zorax
1月前
Monksdream
7月前
SpaceManTrades
2年前
